Actinium Pharma, Inc. (ATNM) Starts Presentation at 2015 Marcum MicroCap Conference

Actinium Pharmaceuticals is a biopharmaceutical company focused on developing drugs to treat cancer. ATNM develops therapies for life threatening diseases using its alpha particle immunotherapy platform. Its product line-up lists Actimab-A and Iomab-B, currently in preparation for a phase 3 multicenter clinical trial for bone marrow conditioning for HSCT in relapsed and refractory AML patients. Founded in 2000, the company is based in New York City. For more information visit the company website at www.actiniumpharma.com